Phio Pharmaceuticals
PHIO
3 hedge funds and large institutions have $1.85M invested in Phio Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0.24% less ownership
Funds ownership: 12% → 11.76% (-0.24%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $140K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$56K |
| 2 |
Virtu KCG Holdings
New York
|
-$43K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$25K |
| 4 |
Goldman Sachs
New York
|
-$5K |
| 5 |
People's United Financial
Bridgeport,
Connecticut
|
-$4K |
PHIO Hedge Fund Activity: Q2 2016 in Review
3 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2016, worth a combined $1.85M — down 13% from $2.11M a quarter earlier.
Fund positioning in PHIO was balanced in Q2 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Susquehanna International Group, cutting an estimated $56K.
- 3 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $1.85M of Phio Pharmaceuticals stock for Q2 2016, down 13% quarter-over-quarter.
- 0 funds opened new Phio Pharmaceuticals positions in Q2 2016 and 0 closed out.
- The largest Phio Pharmaceuticals seller in Q2 2016 was Susquehanna International Group, an estimated $56K sold.
Based on aggregated 13F filings for Q2 2016.